{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:05:03Z","timestamp":1777899903254,"version":"3.51.4"},"reference-count":43,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Tuberculosis (TB) remains a major cause of morbidity and mortality among children worldwide, with approximately one million new pediatric cases annually. The conventional treatment for drug-susceptible TB has long relied on a 6-month multidrug regimen, which is highly effective but associated with challenges in adherence, toxicity, and healthcare burden. Objectives: To evaluate whether short-course therapy is an appropriate regimen for children and young adolescents with drug-susceptible TB, with particular focus on its efficacy, safety, and applicability in different clinical contexts. Methods: A structured narrative review of the literature was conducted, including randomized controlled trials, observational studies, and international guidelines addressing treatment duration in children and young adolescents with drug-susceptible TB. Evidence was synthesized focusing on children and young adolescents &lt;16 years with drug-susceptible TB treated with short-course regimens compared to standard therapy. Results: A shorter treatment regimen, particularly 4-month courses, has been investigated as an alternative to standard therapy in the pediatric population with drug-susceptible TB. Children often present with paucibacillary and non-severe forms of TB, providing a biological rationale for treatment shortening. Evidence from a randomized controlled trial has demonstrated that a 4-month regimen is non-inferior to the standard 6-month therapy in children and young adolescents with non-severe, drug-susceptible TB. These findings have informed recent international guideline updates, which now recommend short therapy in carefully selected patients. However, a short regimen is not appropriate for infants younger than 3 months, children with severe or complicated TB, extrapulmonary disease such as central nervous system involvement, or those with drug-resistant TB. The overall quality of evidence remains moderate, and long-term relapse data are still emerging. Conclusions: Short-course therapy represents a promising but selective strategy in pediatric drug-susceptible TB management. It offers potential advantages, including improved adherence, reduced drug toxicity, and lower healthcare costs. However, its safe implementation requires accurate patient selection, access to appropriate diagnostic tools, and structured follow-up. Careful application within clearly defined clinical criteria is essential to ensure optimal outcomes.<\/jats:p>","DOI":"10.3390\/ph19050721","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:15:27Z","timestamp":1777630527000},"page":"721","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is Short Therapy an Appropriate Regimen for Children and Young Adolescents with Drug-Susceptible Tuberculosis?"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-2837","authenticated-orcid":false,"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-7484","authenticated-orcid":false,"given":"Valentina","family":"Fainardi","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice Rita","family":"Campana","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia Giorgia","family":"Arnesano","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-5568","authenticated-orcid":false,"given":"Nicola","family":"Principi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025). Global Tuberculosis Report 2025, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(14)60420-7","article-title":"Importance of tuberculosis control to address child survival","volume":"383","author":"Graham","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1016\/S2214-109X(17)30289-9","article-title":"The global burden of tuberculosis mortality in children: A mathematical modelling study","volume":"5","author":"Dodd","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_4","first-page":"153","article-title":"Epidemiology and disease burden of tuberculosis in children","volume":"7","author":"Seddon","year":"2014","journal-title":"Infect. Drug Resist."},{"key":"ref_5","first-page":"1155","article-title":"Diagnosis of pulmonary TB in children","volume":"50","author":"Zar","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/adc.2006.104976","article-title":"Diagnosis of childhood tuberculosis","volume":"92","author":"Marais","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10096-015-2507-6","article-title":"Recommendations for the diagnosis of pediatric tuberculosis","volume":"35","author":"Chiappini","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.idc.2015.05.011","article-title":"New diagnostics for childhood TB","volume":"29","author":"Chiang","year":"2015","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_9","first-page":"392","article-title":"The natural history of childhood intra-thoracic tuberculosis","volume":"8","author":"Marais","year":"2004","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1473-3099(15)00007-9","article-title":"Toward early inclusion of children in tuberculosis drug trials: A consensus statement","volume":"15","author":"Nachman","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"ATS\/CDC\/IDSA TB treatment guidelines","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/INF.0000000000001721","article-title":"Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic","volume":"37","author":"Gaensbauer","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101676","DOI":"10.1016\/j.lanepe.2026.101676","article-title":"Treatment outcomes and long-term relapse-free survival after multidrug-resistant tuberculosis treatment in Latvia: A retrospective national cohort study","volume":"65","author":"Meier","year":"2026","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_14","first-page":"292","article-title":"Adherence to TB treatment","volume":"15","author":"Boeree","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2104535","article-title":"Shorter treatment for nonsevere tuberculosis in African and Indian children (SHINE): A randomised trial","volume":"386","author":"Turkova","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"Patient-level pooled analysis of TB regimens","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S1473-3099(23)00004-X","article-title":"Post-tuberculosis sequelae in children and adolescents: A systematic review","volume":"23","author":"Igbokwe","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1440-1843.2010.01784.x","article-title":"Tuberculosis at extremes of age","volume":"15","author":"Schaaf","year":"2010","journal-title":"Respirology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0041-3879(85)90040-6","article-title":"The action of antituberculosis drugs in short-course chemotherapy","volume":"66","author":"Mitchison","year":"1985","journal-title":"Tubercle"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(20)30166-5","article-title":"The risk of tuberculosis in children after close exposure: A systematic review and individual-participant meta-analysis","volume":"395","author":"Martinez","year":"2020","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri3813","article-title":"Advancing host-directed therapy for tuberculosis","volume":"15","author":"Wallis","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2201596","DOI":"10.1183\/13993003.01596-2022","article-title":"Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: A systematic review and individual patient data meta-analysis","volume":"61","author":"Gafar","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/598192","article-title":"Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: Implications for international pediatric dosing guidelines","volume":"48","author":"McIlleron","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/INF.0b013e318243e27b","article-title":"Classification of TB severity in children","volume":"31","author":"Wiseman","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for TB","volume":"371","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin regimen for for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_29","unstructured":"World Health Organization (2022). WHO Consolidated Guidelines on Tuberculosis. Module 5: Management of Tuberculosis in Children and Adolescents, World Health Organization."},{"key":"ref_30","unstructured":"World Health Organization (2022). WHO Operational Handbook on Tuberculosis. Module 5: Children and Adolescents, World Health Organization."},{"key":"ref_31","unstructured":"National Institute for Health and Care Excellence (2016). Tuberculosis (NG33), NICE."},{"key":"ref_32","unstructured":"Public Health Agency of Canada (2022). Canadian Tuberculosis Standards, Canadian Thoracic Society (CTS). [8th ed]."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Diagnosis of TB in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(15)00095-8","article-title":"Xpert MTB\/RIF in children","volume":"3","author":"Detjen","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_35","unstructured":"World Health Organization (2025). WHO Guidelines on Drug-Resistant TB Treatment, WHO."},{"key":"ref_36","first-page":"2000213","article-title":"TB sequelae and follow-up","volume":"56","author":"Tadolini","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40272-015-0155-z","article-title":"Recommendations Concerning the First-Line Treatment of Children with Tuberculosis","volume":"18","author":"Principi","year":"2016","journal-title":"Paediatr. Drugs"},{"key":"ref_38","first-page":"375","article-title":"Risk factors for adverse TB outcomes in children","volume":"54","author":"Seddon","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.ijid.2023.03.023","article-title":"Multidrug-resistant tuberculosis in children: Are the same therapy options available worldwide?","volume":"130","author":"Buonsenso","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17512433.2023.2148653","article-title":"Treatment options for children with multi-drug resistant tuberculosis","volume":"16","author":"Autore","year":"2023","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.phrs.2016.01.020","article-title":"Recommendations for treating children with drug-resistant tuberculosis","volume":"105","author":"Galli","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/jp.2015.99","article-title":"How to manage neonatal tuberculosis","volume":"36","author":"Esposito","year":"2016","journal-title":"J. Perinatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clinthera.2015.10.012","article-title":"Recommendations Concerning the Therapeutic Approach to Immunocompromised Children With Tuberculosis","volume":"38","author":"Lancella","year":"2016","journal-title":"Clin. Ther."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:17:51Z","timestamp":1777630671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ph19050721"],"URL":"https:\/\/doi.org\/10.3390\/ph19050721","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}